News
05-30-2009, 04:18 AM
Genomic Health, Inc. (Nasdaq: GHDX) today announced results from a study which summarized the gene signatures identified by the Oncotype DX(R) breast cancer test in a large number of male patients for whom the test was used to guide treatment with chemotherapy. The results, which will be presented in a poster presentation on Monday, June 1 (1:00 - 5:00 p.m.
More... (http://www.medicalnewstoday.com/articles/151960.php)
More... (http://www.medicalnewstoday.com/articles/151960.php)